Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Worcester › NPI 1093793200
Lab

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings was paid $3.20M by Medicaid between Jan 2018 and Dec 2024, across 201 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 8.5% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
WORCESTER, MA 01608
33aNPI1093793200assigned 01/06/2006
33bProvider typeClinical Medical Laboratory
28Total paid$3.20M
24GClaims180,289
24DCodes billed201
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Massachusetts

Rank by total paid#13 of 63
Median peer was paid$473K
This provider vs. median6.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20189,343$29K
20195,740$20K
20205,681$124K
20217,230$196K
20223,242$61K
20233,069$38K
2024incomplete145,984$2.73M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 8.5% 3,235 3,106 $271K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 8.2% 6,205 3,130 $260K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.9% 6,627 6,463 $190K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.9% 6,520 6,362 $187K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 5.2% 2,954 2,887 $165K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 3.2% 3,640 3,557 $102K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 3.0% 675 670 $96K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 3.0% 121 121 $96K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 2.1% 3,586 3,532 $69K
80050 General health panel 2.1% 1,599 1,586 $68K
80053 Comprehensive metabolic panel 2.1% 11,475 10,527 $66K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 2.0% 561 544 $63K
189 more codes
86480 1.9% 1,265 $62K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1.9% 2,659 $62K
84443 Thyroid stimulating hormone (TSH) 1.8% 4,792 $57K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.6% 64 $51K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1.6% 2,020 $51K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.5% 534 $49K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.5% 10,897 $47K
81257 1.4% 57 $45K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.4% 1,013 $43K
80061 Lipid panel 1.2% 4,304 $39K
85027 1.2% 7,833 $39K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.2% 1,320 $37K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.1% 1,716 $36K
86780 1.1% 3,352 $36K
86803 1.1% 3,081 $35K
87536 1.0% 487 $33K
87086 Culture, bacterial; quantitative colony count, urine <1% 5,190 $31K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 577 $30K
83036 Hemoglobin; glycosylated (A1C) <1% 3,385 $25K
81255 <1% 57 $24K
87631 <1% 214 $24K
80048 Basic metabolic panel (calcium, ionized) <1% 4,291 $24K
87507 <1% 69 $23K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 147 $21K
84702 <1% 1,030 $21K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 491 $21K
83013 <1% 367 $20K
82607 <1% 1,638 $20K
83655 <1% 1,961 $19K
82728 <1% 1,775 $19K
87081 <1% 3,354 $17K
87150 <1% 586 $16K
83880 <1% 507 $16K
87340 <1% 1,892 $15K
86003 <1% 260 $15K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 175 $14K
83970 <1% 409 $13K
84439 <1% 1,759 $12K
87522 Neg quan hep c or qual rna <1% 367 $12K
83550 <1% 2,084 $12K
81243 <1% 65 $12K
84403 <1% 535 $12K
86317 <1% 929 $11K
81251 <1% 57 $11K
86762 <1% 955 $11K
83540 <1% 2,231 $10K
82746 <1% 810 $9K
82570 <1% 1,981 $8K
81200 <1% 57 $8K
84460 <1% 1,673 $7K
81001 <1% 2,724 $7K
84402 <1% 334 $7K
86364 <1% 593 $7K
82043 <1% 1,481 $7K
84146 <1% 417 $6K
82670 <1% 288 $6K
82784 <1% 643 $6K
81329 <1% 58 $6K
87186 <1% 879 $6K
86787 <1% 605 $6K
86704 <1% 638 $6K
ATP14 <1% 2,490 $6K
83001 <1% 399 $6K
83735 <1% 1,284 $6K
84450 <1% 1,351 $5K
87468 <1% 104 $5K
86140 <1% 1,281 $5K
87088 <1% 788 $5K
80076 <1% 734 $5K
86765 <1% 458 $5K
83718 <1% 717 $5K
86735 <1% 429 $4K
86038 <1% 453 $4K
85610 <1% 1,840 $4K
84481 <1% 280 $4K
83721 <1% 452 $4K
82565 <1% 974 $4K
87476 <1% 130 $4K
84270 <1% 205 $4K
83002 <1% 235 $3K
86235 <1% 72 $3K
81242 <1% 57 $3K
87563 <1% 100 $3K
86618 <1% 233 $3K
87077 <1% 487 $3K
82248 <1% 1,069 $3K
80069 <1% 514 $3K
87529 <1% 94 $3K
85652 <1% 1,361 $3K
82785 <1% 222 $3K
83921 <1% 166 $3K
82465 <1% 748 $3K
81209 <1% 57 $3K
85018 <1% 1,358 $3K
86708 <1% 249 $2K
84153 <1% 164 $2K
83993 <1% 150 $2K
82950 <1% 605 $2K
87070 <1% 319 $2K
86200 <1% 212 $2K
83690 <1% 382 $2K
86376 <1% 173 $2K
86592 <1% 571 $2K
82533 <1% 147 $2K
82627 <1% 108 $2K
82105 <1% 104 $2K
82550 <1% 357 $2K
81003 <1% 1,278 $2K
86431 <1% 402 $2K
80051 <1% 308 $2K
84550 <1% 480 $2K
86160 <1% 87 $2K
84156 <1% 557 $2K
84100 <1% 479 $2K
83020 <1% 148 $2K
80074 <1% 40 $2K
86008 <1% 12 $1K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 65 $1K
80197 <1% 151 $1K
84520 <1% 430 $1K
86258 <1% 68 $1K
82947 <1% 323 $1K
88142 <1% 59 $948.72
87338 <1% 79 $901.39
82977 <1% 151 $859.44
82310 <1% 211 $856.90
82951 <1% 81 $827.82
87209 <1% 58 $827.66
85730 <1% 183 $817.60
83520 <1% 53 $754.04
80164 <1% 69 $741.75
82274 <1% 55 $695.20
81596 <1% 12 $687.60
36415 Collection of venous blood by venipuncture <1% 3,430 $684.63
85060 <1% 14 $659.87
ATP08 <1% 324 $643.74
84436 <1% 118 $643.10
83615 <1% 184 $597.64
82247 <1% 181 $585.80
83498 <1% 27 $582.12
87205 <1% 164 $559.97
81025 <1% 80 $546.40
84445 <1% 13 $524.81
84155 <1% 177 $516.84
85014 <1% 275 $516.06
84466 <1% 50 $506.50
84165 <1% 61 $491.00
86850 <1% 62 $481.12
86225 <1% 43 $469.13
87625 <1% 14 $450.52
86665 <1% 16 $446.40
82150 <1% 83 $427.25
85379 <1% 58 $424.76
84075 <1% 97 $398.67
86696 <1% 25 $384.00
83014 <1% 61 $380.64
87427 <1% 40 $380.40
86800 <1% 27 $341.01
87177 <1% 46 $325.22
87045 <1% 42 $315.00
87046 <1% 41 $307.50
87075 <1% 37 $293.26
86304 <1% 16 $264.32
82952 <1% 81 $258.15
ATP15 <1% 82 $237.57
86334 <1% 13 $230.49
84425 <1% 13 $219.05
80299 <1% 14 $207.20
86308 <1% 49 $201.39
86901 <1% 79 $188.02
86900 <1% 79 $188.02
85045 <1% 58 $183.86
86664 <1% 15 $182.10
86705 <1% 17 $158.78
86593 <1% 44 $153.56
84480 <1% 13 $146.25
82330 <1% 13 $141.05
82040 <1% 33 $129.69
86695 <1% 12 $125.64
86709 <1% 14 $125.16
86141 <1% 12 $123.36
85048 <1% 57 $117.15
86706 <1% 13 $110.76
84132 <1% 25 $94.50
80178 <1% 17 $89.25
ATP10 <1% 28 $76.96
84295 <1% 17 $64.94
82435 <1% 16 $58.40
ATP18 <1% 17 $21.94

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.